Peptide side effects
Every medication that does something can do something unwanted. These articles catalogue peptide side effects and those reported for GLP-1 medications — nausea, injection-site reactions, and the rarer things worth knowing about — plus what researchers report about how long effects last and what tends to help.
Honest side-effect information is a feature, not a liability: it's how you and your provider decide together whether a treatment fits. Where an effect has its own article — nausea, hair shedding, fatigue — you'll find the detail there.
118 articles on this topic
-
Does Semaglutide Cause Dizziness? What Labels Say
Yes, dizziness can happen. The Wegovy and Ozempic labels give different levels of detail; fluid loss, blood sugar, and blood pressure help explain what a provider checks.
-
TAZPOWER Trial: What the Results Actually Show
TAZPOWER missed its main walking and fatigue goals against placebo. Longer follow-up reported gains, with enough uncertainty to require another trial.
-
GLP-1 Vision Loss Study: Small Added Eye Risk Explained
October headlines revisited a 2026 diabetes study finding 3 to 4 extra coded optic-nerve cases per 10,000 people over 18 months. Here is what those numbers mean, how U.S. and European guidance differ, and why sudden vision loss needs immediate care.
-
Does Tirzepatide Cause Headaches? What Trials Show
Headaches occurred in about 7 in 100 people in SURMOUNT-1, with similar rates on placebo. Fluid loss, missed meals, and other medicines can still matter.
-
MMPOWER-3 Trial: Walking and Fatigue Goals Not Met
After 24 weeks, elamipretide did not beat placebo on walking distance or fatigue. A later genetic subgroup finding led to another trial, not a new verdict.
-
Thymosin Alpha 1 Sepsis Trial: What TESTS Found
TESTS found no clear reduction in sepsis deaths: 23.4% with thymosin alpha-1 versus 24.1% with placebo. Its subgroup findings remain tentative.
-
Does Tirzepatide Cause Acid Reflux? It Can
Tirzepatide can cause reflux and indigestion. The brand labels show how often each was reported, while persistent or severe symptoms need a clinician's review.
-
Feeling Cold on Tirzepatide: An Autumn Guide
Feeling chilly can accompany weight loss, but persistent coldness deserves a closer look. Here's what the labels say and what cold weather means for storage.
-
Ozempic Face: What Facial Changes Really Mean
Ozempic face means a face looking less full after weight loss. Small studies document changes, but they cannot settle whether the drug has a direct effect.
-
STRIDE Trial Semaglutide: Walking Results
Semaglutide was associated with better treadmill walking in people with leg artery disease and type 2 diabetes. Here are the numbers, side effects and limits of STRIDE.
-
Egrifta Prescribing Information, Explained
Egrifta WR’s label covers one HIV-related use, a daily dose, four contraindications, monitoring, side effects, and product-specific storage. WR and SV directions cannot be swapped.
-
STEP 5 Trial Results: Semaglutide at Two Years
In STEP 5, average weight loss was 15.2% with semaglutide versus 2.6% with placebo at two years. The plateau, side effects and two calculations explain what held up.
-
What Is Dose Titration? Why Doses Change in Steps
Dose titration means changing a dose in steps while checking response and side effects. A gradual climb has a purpose, and the highest dose isn’t everyone’s destination.
-
Semaglutide and Gout: It Isn't a Gout Treatment
Semaglutide may lower uric acid, but fewer gout attacks remain unproven. New findings make a gout history and a flare plan part of the prescribing conversation.
-
Tesamorelin Fatty Liver Trial: What It Found
A 12-month trial found less liver fat and less worsening of scarring with tesamorelin. Its 61 participants had HIV, a virus that weakens the immune system, which limits what the findings mean for everyone else.
-
OASIS 4 Trial Results: 13.6% Weight Loss Explained
The daily 25 mg tablet averaged 13.6% weight loss versus 2.2% with placebo at 64 weeks. The 16.6% headline assumes continued treatment.
-
10 Questions to Ask Before PT-141
A PT-141 visit starts with fit and safety. These ten questions clarify the evidence, medical history, side effects, and follow-up plan.
-
Does Semaglutide Cause Thyroid Cancer?
Human studies have not established that semaglutide causes thyroid cancer. The warning comes from tumors in rats and mice, and specific cancer histories rule out use.
-
Forzinity Prescribing Information: Plain English
Forzinity’s label covers Barth syndrome, a daily injection, and specific safety limits. Here’s what each section means.
-
Semax Side Effects: What the Safety Data Shows
Mild nasal irritation is documented, but reliable rates for other reactions are missing. The small studies leave important safety questions unanswered.
Page 1 of 6 · 118 articles